During AHA 2024, data were presented from the Phase III trial of plozasiran targ...
At AHA 2024, clinical trial results were presented from the ongoing open-label e...
The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo...
Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide a...
EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European U...
AstraZeneca will advance preclinical and clinical development of the Type 1 Diab...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American...
The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment...
The decision in Europe follows an approval granted by the US Food and Drug Admin...
The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treatin...
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use...
AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following...
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ ...
Revenue for the mpox vaccine is down compared to last year however its travel va...
The company has discontinued the Phase I/II trial of its only clinical candidate...
Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therap...
